Latest Telaprevir Stories
- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV)
- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH
LONDON, March 17, 2015 /PRNewswire/ -- Report DetailsHepatitis C treatments - your guide to medical needs, R&D trends and future drug revenuesDiscover the future of treating
DALLAS, January 23, 2015 /PRNewswire/ -- LifeScienceIndustryResearch.com adds Hepatitis C Global Clinical Trials Review, H2, 2014 as well as Hepatitis C Market & Forecast,
-- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients -- In Phase 3 clinical trials, HOLKIRA
LONDON, December 17, 2014 /PRNewswire/ -- Report Details Hepatitis C treatments - your guide to medical needs, R&D trends and future drug revenues Discover
- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.
MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29,
Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat.
- an ornament or knob in the shape of a flower